# Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct07365358` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07365358](<https://clinicaltrials.gov/study/NCT07365358>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07365358

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07365358. Randomized; no masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2027-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07365358, source copy `cardio:ctgov-nct07365358-2026-01-26`, retrieved 2026-10-26)
- Planned start: 2026-03 (anticipated) (ClinicalTrials.gov record NCT07365358, source copy `cardio:ctgov-nct07365358-2026-01-26`, retrieved 2026-10-26)
- Primary completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07365358, source copy `cardio:ctgov-nct07365358-2026-01-26`, retrieved 2026-10-26)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07365358, source copy `cardio:ctgov-nct07365358-2026-01-26`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07365358, source copy `cardio:ctgov-nct07365358-2026-01-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07365358-2026-01-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
- Acronym: EMPAGO
- Condition: Diabete Type 2
- Intervention (Drug): empagliflozin 10mg
- Intervention (Drug): Glimepiride 1mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: dc2812737c7a2ee24d337ab9d4e7027d951a0d342d4754101eb2e6b9a38e6116
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
